CU20090107A7 - Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasa - Google Patents
Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasaInfo
- Publication number
- CU20090107A7 CU20090107A7 CU20090107A CU20090107A CU20090107A7 CU 20090107 A7 CU20090107 A7 CU 20090107A7 CU 20090107 A CU20090107 A CU 20090107A CU 20090107 A CU20090107 A CU 20090107A CU 20090107 A7 CU20090107 A7 CU 20090107A7
- Authority
- CU
- Cuba
- Prior art keywords
- derivatives
- inhibodires
- dihydropiridine
- useful
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
La presente invención provee nuevos derivados de dihidropiridina de la fórmula I ESPACIO PARA LA FÓRMULA que tienen una actividad inhibidora de la proteína tirosina quinasa, a un proceso para su preparación y a su uso para el tratamiento de enfermedades mediadas por c-Met o condiciones patológicas mediadas por c-Met
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87512406P | 2006-12-14 | 2006-12-14 | |
PCT/EP2007/011076 WO2008071451A1 (en) | 2006-12-14 | 2007-12-12 | Dihydropyridine derivatives useful as protein kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
CU20090107A7 true CU20090107A7 (es) | 2012-02-15 |
CU23828A3 CU23828A3 (es) | 2012-06-29 |
CU23828B1 CU23828B1 (es) | 2012-06-29 |
Family
ID=39262588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20090107A CU23828B1 (es) | 2006-12-14 | 2009-06-12 | Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasa |
Country Status (32)
Country | Link |
---|---|
US (1) | US8198456B2 (es) |
EP (1) | EP2121608B1 (es) |
JP (2) | JP2010513231A (es) |
KR (1) | KR20090087919A (es) |
CN (1) | CN101558040B (es) |
AR (1) | AR064349A1 (es) |
AU (1) | AU2007331676A1 (es) |
BR (1) | BRPI0719991A2 (es) |
CA (1) | CA2672167C (es) |
CL (1) | CL2007003609A1 (es) |
CO (1) | CO6210730A2 (es) |
CR (1) | CR10868A (es) |
CU (1) | CU23828B1 (es) |
DO (1) | DOP2009000141A (es) |
EA (1) | EA200900779A1 (es) |
EC (1) | ECSP099414A (es) |
ES (1) | ES2396160T3 (es) |
HK (1) | HK1135103A1 (es) |
HN (1) | HN2009001165A (es) |
IL (1) | IL198171A0 (es) |
MA (1) | MA31090B1 (es) |
MX (1) | MX2009006267A (es) |
MY (1) | MY148851A (es) |
NO (1) | NO20092651L (es) |
NZ (1) | NZ577611A (es) |
PE (1) | PE20081510A1 (es) |
SG (1) | SG177200A1 (es) |
SV (1) | SV2009003299A (es) |
TN (1) | TN2009000128A1 (es) |
TW (1) | TW200836729A (es) |
UY (1) | UY30779A1 (es) |
WO (1) | WO2008071451A1 (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110301155A1 (en) * | 2007-06-19 | 2011-12-08 | Tsuneo Yasuma | Indazole compounds for activating glucokinase |
JP5506788B2 (ja) * | 2008-06-09 | 2014-05-28 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換4−(インダゾリル)−1,4−ジヒドロピリジン類およびそれらの使用方法 |
US8642595B2 (en) * | 2008-06-09 | 2014-02-04 | Bayer Intellectual Property Gmbh | Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof |
WO2010094405A1 (en) | 2009-02-18 | 2010-08-26 | Bayer Schering Pharma Aktiengesellschaft | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof |
EP2451817B1 (en) * | 2009-07-10 | 2013-09-04 | Bayer Intellectual Property GmbH | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof |
DK2987487T3 (da) | 2009-08-10 | 2020-12-07 | Samumed Llc | Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf |
JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
CA2773467C (en) * | 2009-10-06 | 2017-07-04 | Bayer Pharma Aktiengesellschaft | Fluorinated 2,6-dialkyl-3,5-dicyano-4-(1h-indazol-5-yl)-1,4-dihydropyridines and methods of use thereof |
UY32922A (es) * | 2009-10-06 | 2011-04-29 | Bayer Schering Pharma Ag | Derivados de 3, 5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos |
WO2011069761A1 (en) | 2009-11-11 | 2011-06-16 | Bayer Schering Pharma Aktiengesellschaft | Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof |
ES2449916T3 (es) | 2009-11-18 | 2014-03-21 | Bayer Intellectual Property Gmbh | Derivados de 1,4-dihidropiridina sustituidos con furopiridinilo y procedimientos de uso de los mismos |
DE102009056886A1 (de) | 2009-12-03 | 2011-06-09 | Bayer Schering Pharma Aktiengesellschaft | cMet-Inhibitoren zur Behandlung der Endometriose |
AU2010330894A1 (en) | 2009-12-18 | 2012-07-05 | Janssen Pharmaceutica Nv | Substituted aminothiazolone indazoles as estrogen related receptor-aalpha modulators |
DK3001903T3 (en) | 2009-12-21 | 2017-12-18 | Samumed Llc | 1H-PYRAZOLO [3,4 -?] PYRIDINES AND THERAPEUTIC APPLICATIONS THEREOF |
US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
MX2013006467A (es) | 2010-12-09 | 2013-10-01 | Amgen Inc | Compuestos biciclicos como inhibidores pim. |
JP2014510105A (ja) | 2011-03-22 | 2014-04-24 | アムジエン・インコーポレーテツド | Pim阻害剤としてのアゾール化合物 |
AU2012308570B2 (en) | 2011-09-14 | 2016-11-10 | Samumed, Llc | Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors |
CN103204844A (zh) | 2012-01-17 | 2013-07-17 | 上海艾力斯医药科技有限公司 | 氨基杂芳基化合物及其制备方法与应用 |
CN103319456B (zh) * | 2012-03-23 | 2015-05-13 | 上海汇伦生命科技有限公司 | 二氢吡啶类化合物、其组合物、制备方法和用途 |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
DK2770994T3 (da) | 2012-05-04 | 2019-11-11 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridiner og terapeutiske anvendelser deraf |
CN105120862A (zh) | 2013-01-08 | 2015-12-02 | 萨穆梅德有限公司 | Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用 |
US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
EP3089746A4 (en) * | 2013-12-30 | 2017-08-30 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
CA2954814A1 (en) * | 2014-07-16 | 2016-01-21 | Lifesci Pharmaceuticals, Inc. | Isonicotinamide compounds and their use as plasma kallikrein inhibitors |
WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
US10392383B2 (en) | 2015-08-03 | 2019-08-27 | Samumed, Llc | 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10226453B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
WO2017024026A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
US10188634B2 (en) | 2015-08-03 | 2019-01-29 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
WO2017024021A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
CA3004297A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
US20190016680A1 (en) | 2016-01-14 | 2019-01-17 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
KR102417686B1 (ko) | 2016-04-20 | 2022-07-07 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 비시클릭 헤테로시클릭 화합물 |
PL3464285T3 (pl) | 2016-06-01 | 2023-02-06 | Biosplice Therapeutics, Inc. | Sposób wytwarzania n-(5-(3-(7-(3-fluorofenylo)-3h-imidazo[4,5-c]pirydyn-2-ylo)-1h-indazol-5-ilo)pirydyn-3-ylo)-3-metylobutanoamidu |
WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
JP2019535672A (ja) | 2016-10-21 | 2019-12-12 | サミュメッド リミテッド ライアビリティ カンパニー | インダゾール−3−カルボキサミドの使用方法およびwnt/β−カテニンシグナル伝達経路阻害剤としてのそれらの使用 |
MA46696A (fr) | 2016-11-07 | 2019-09-11 | Samumed Llc | Formulations injectables à dose unique prêtes à l'emploi |
EP3480201A1 (en) * | 2017-11-06 | 2019-05-08 | Oncostellae, S.L. | New analogs as androgen receptor and glucocorticoid receptor modulators |
WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
CA3095233A1 (en) | 2018-03-28 | 2019-10-03 | Bayer Pharma Aktiengesellschaft | 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders |
CN110078707A (zh) * | 2019-06-03 | 2019-08-02 | 上海贤鼎生物科技有限公司 | 一种2-(1H-苯并[d]咪唑-2-基)-8-羟基喹啉的合成方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS162291B1 (es) | 1973-04-26 | 1975-07-15 | ||
PL86477B1 (es) | 1973-09-01 | 1976-05-31 | ||
CS168272B1 (es) | 1973-09-18 | 1976-05-28 | ||
GB1457787A (en) * | 1974-05-17 | 1976-12-08 | Wyeth John & Brother Ltd | Dihydropyridines |
CS191511B1 (en) * | 1976-09-06 | 1979-07-31 | Jaroslav Palecek | Process for preparing 1-dialkylaminoalkyl-2,6-dimethyl-4-/y-substituted phenyl/-3,5-disubstituted 1,4-dihydropyridines |
GB9515445D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | Dihydropyridine and pyridine derivatives and process for their preparation |
US6265127B1 (en) | 1999-12-15 | 2001-07-24 | Eastman Kodak Company | 1, 4-dihydrophyridine charge control agents for electrostatographic toners and developers |
US6790852B2 (en) | 2002-04-18 | 2004-09-14 | Hoffmann-La Roche Inc. | 2-(2,6-dichlorophenyl)-diarylimidazoles |
GEP20084341B (en) | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
BRPI0412040A (pt) | 2003-07-02 | 2006-09-05 | Sugen Inc | hidrazidas de indolinona como inibidores de c-met |
JP2007230869A (ja) * | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | アルドステロン受容体拮抗剤 |
CN101018780B (zh) | 2004-08-26 | 2012-01-11 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的吡唑取代的氨基杂芳基化合物 |
AP2470A (en) | 2004-09-09 | 2012-09-17 | Natco Pharma Ltd | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase |
KR20070087602A (ko) * | 2004-12-13 | 2007-08-28 | 아이알엠 엘엘씨 | 화합물 및 스테로이드성 수용체 및 칼슘 채널 활성의조절제로서의 조성물 |
US20060188938A1 (en) | 2005-01-07 | 2006-08-24 | Mullan Michael J | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds |
CN101472915A (zh) | 2006-04-19 | 2009-07-01 | 诺瓦提斯公司 | 吲唑化合物和抑制cdc7的方法 |
-
2007
- 2007-12-12 JP JP2009540667A patent/JP2010513231A/ja not_active Withdrawn
- 2007-12-12 KR KR1020097012149A patent/KR20090087919A/ko not_active Application Discontinuation
- 2007-12-12 CL CL200703609A patent/CL2007003609A1/es unknown
- 2007-12-12 BR BRPI0719991-0A2A patent/BRPI0719991A2/pt not_active IP Right Cessation
- 2007-12-12 WO PCT/EP2007/011076 patent/WO2008071451A1/en active Application Filing
- 2007-12-12 MX MX2009006267A patent/MX2009006267A/es active IP Right Grant
- 2007-12-12 UY UY30779A patent/UY30779A1/es not_active Application Discontinuation
- 2007-12-12 CN CN2007800460111A patent/CN101558040B/zh not_active Expired - Fee Related
- 2007-12-12 CA CA2672167A patent/CA2672167C/en not_active Expired - Fee Related
- 2007-12-12 MY MYPI20092439A patent/MY148851A/en unknown
- 2007-12-12 ES ES07856810T patent/ES2396160T3/es active Active
- 2007-12-12 EA EA200900779A patent/EA200900779A1/ru unknown
- 2007-12-12 EP EP07856810A patent/EP2121608B1/en active Active
- 2007-12-12 AU AU2007331676A patent/AU2007331676A1/en not_active Abandoned
- 2007-12-12 NZ NZ577611A patent/NZ577611A/en not_active IP Right Cessation
- 2007-12-12 SG SG2011091568A patent/SG177200A1/en unknown
- 2007-12-13 PE PE2007001781A patent/PE20081510A1/es not_active Application Discontinuation
- 2007-12-13 US US11/955,777 patent/US8198456B2/en not_active Expired - Fee Related
- 2007-12-13 TW TW096147740A patent/TW200836729A/zh unknown
- 2007-12-14 AR ARP070105619A patent/AR064349A1/es unknown
-
2009
- 2009-04-08 TN TNP2009000128A patent/TN2009000128A1/fr unknown
- 2009-04-16 IL IL198171A patent/IL198171A0/en unknown
- 2009-06-12 CR CR10868A patent/CR10868A/es unknown
- 2009-06-12 CO CO09061399A patent/CO6210730A2/es not_active Application Discontinuation
- 2009-06-12 DO DO2009000141A patent/DOP2009000141A/es unknown
- 2009-06-12 EC EC2009009414A patent/ECSP099414A/es unknown
- 2009-06-12 CU CU20090107A patent/CU23828B1/es not_active IP Right Cessation
- 2009-06-12 HN HN2009001165A patent/HN2009001165A/es unknown
- 2009-06-12 SV SV2009003299A patent/SV2009003299A/es unknown
- 2009-07-09 MA MA32082A patent/MA31090B1/fr unknown
- 2009-07-13 NO NO20092651A patent/NO20092651L/no not_active Application Discontinuation
-
2010
- 2010-04-06 HK HK10103376.6A patent/HK1135103A1/xx not_active IP Right Cessation
-
2014
- 2014-02-28 JP JP2014039100A patent/JP6021838B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20090107A7 (es) | Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasa | |
ECSP088210A (es) | Bencimidazoles sustituidos y métodos de preparación | |
CR10072A (es) | Derivados de pirimidinil-aril-urea que son inhibidores de fgf | |
UY32848A (es) | Compuestos heterocíclicos de oxima | |
CU20110129A7 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
CR10211A (es) | Compuestos de tiazol y métodos de uso | |
DE602007004092D1 (de) | C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
BRPI0915105A2 (pt) | composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
BRPI0716844A2 (pt) | Inidores de quinase úteis para o tratamento de doenças proliferativas | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
BRPI0906618A2 (pt) | Derivados de diazepinorimidona de arilamida substituídos para o tratamento de doenças neu-rodegenerativas causadas por atividade anorma de gsk3-beta | |
BRPI0911577A8 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
CO6630193A2 (es) | Inhibidores de la actividad de la proteína tirosina quinasa seleccionada | |
AR074379A1 (es) | Inhibidor de triazolotiadiazola de la proteina quinasa c-met | |
UY29358A1 (es) | Tiazolidinonas, su preparacion y su uso como medicamento | |
UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
UY31143A1 (es) | Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas | |
CR20120150A (es) | Derivados de 3,5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos | |
CU20080120A7 (es) | Derivados de pirimidinil aril urea e inhibidores fgf | |
CY1114207T1 (el) | Παραγωγα βενζοφουρανυλιου για χρηση ως αναστολεις γλυκοκινασης | |
CL2010001491A1 (es) | Compuestos derivados de isoquinolinas; composicion farmaceutica; y su uso para tratar y prevenir enfermedades asociadas con quinasa-rho o quinasa rho mediada por fosforilacion de fosfatasa de cadena ligera de miosina como hipertension ocular, hipertension pulmonar, hipertrofia cardiaca, enfermedades pulmonar obstructiva, alzheimer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent | ||
FD | Lapse (for not paying fees) |